A new research paper by researchers in Peru describes a new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as the Lambda variant (C.37). The Lambda variant was first reported in Lima, Peru, in December 2020, and from April 2021, nearly all the coronavirus infections in the country are caused by it.
The Lambda variant has seven mutations in the spike gene and a deletion in the ORF1a gene. The deletion of the ORF1a gene has been observed in other variants of concern, including Alpha (B.1.1.7), Beta (B.1351), and Gamma (P.1).
Gamma is currently dominant in Central and South America, but Lambda’s high transmission rate may soon overtake it. The study authors write:
“Expansion of C.37 has occurred in South America in the presence of hundreds of circulating lineages and VOCs Alpha and Gamma, suggesting increased transmissibility of this lineage. However, additional epidemiological data and analyses are needed to assess its transmission, virulence, and immune escape properties.”
Vaccines may help in neutralizing the Lambda variant. Although, vaccination rates in South America continue to be low for various reasons. Increased vaccination in the country could prevent Lambda from becoming a variant of concern.
The article “The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America” was recently published on the preprint medRxiv* server, prior to peer review.
From May 31, 2021, Peru has had 0.54% of its country succumb to SARS-CoV-2 — the highest rate of COVID-19 deaths globally relative to the population.
Genomic surveillance is routinely performed to look at lineages of SARS-CoV-2 in the population. In this report, genomes from the Peruvian population were analyzed at the Universidad Perunana Cayetano Heredia and Instituto Nacional de Salud.
The researchers compared the genomes to thousands of sequenced SARS-CoV-2 genomes from Argentina and Chile. SARS-CoV-2 genome assemblies were also downloaded for Peru via GISAID. By June 2021, GISAID had 1,424 genome sequences from 64 circulating lineages in Peru.
Relative frequencies of predominant SARS-CoV-2 lineages in Argentina, Chile, and Peru from November 2020 to May 2021.
Formation and spread of Lambda
The earliest record for the Lambda variant was in November 2020 in Argentina. In December 2020, genomic surveillance revealed the Lambda variant comprised 0.5% of infections in Lima, Peru. Genomic surveillance showed a deep-branching sublineage of B.1.1.1 (Lambda).
From its initial detection, the prevalence of the Lambda variant in Peru has increased over time — 20.5% in January, 36.4% in February, 79.2% in March, and 96.6% in April 2021.
With the increase of Lambda, other SARS-CoV-2 decreased over time. In the last four months, the Alpha variant made up 0.5% of the Peruvian population while the Gamma variant comprised of 1.2%.
Detection of Lambda in other South American countries
By June 19, 2021, there have been 1,771 sequences related to the Lambda variant across 25 countries, including Chile, the United States, Peru, Argentina, Germany, Mexico, Spain, and Ecuador.
Chile and Argentina have experienced a rise in COVID-19 cases related to the Lambda variant. From April 2021, the variant made up 33% of Chile and 12% of Argentina’s genomic sequences.
“The emergence of this lineage in Peru and its export to other countries is a current hypothesis, given its earlier detection and rise to nearly 100% of public sequences by April. We are sequencing additional Peruvian samples from October to December 2020 to confirm and date the origin of C.37,” wrote the study authors.
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.